Antares Therapeutics

Antares is a biopharmaceutical entity concentrated on pioneering precision medicine, with a primary emphasis on oncology. The firm's genesis lies in the March 2025 acquisition of Scorpion Therapeutics by Lilly, enabling Antares to leverage Scorpion's established discovery capabilities and validated therapeutic pipeline.

Guidance is provided by an executive team with prior experience at Scorpion Therapeutics. Dr. Adam Friedman, with a background as a physician, scientist, and notable experience in oncology, leads as Chief Executive Officer. Amanda Valentino serves as Chief People Officer, contributing over two decades of experience in life sciences talent, human resources, and M&A.

Antares's operational strategy involves pushing scientific boundaries to develop novel therapies. The company's stated mission is to shape the future of precision medicine and deliver treatments that can transform patient lives, particularly within the oncology space. The target market encompasses advanced cancer therapeutics. The business model, characteristic of therapeutics firms, centers on research and development of new drugs, followed by clinical validation and eventual commercialization. The acquisition of its predecessor's assets by Lilly underscores the perceived value of its scientific platform and pipeline.

Keywords: Oncology, Precision Medicine, Therapeutics, Biopharmaceutical, Drug Development, Cancer Treatment, R&D, Pipeline, Life Sciences, Executive Leadership